| Objective To summarize and analyze the clinical experience and outcomes of minimally invasive total hip arthroplasty (THA) via the direct anterior approach for end-stage hip arthropathy in uremic patients.Methods A retrospective analysis was conducted on 10 uremic patients (10 hips) who underwent THA via the direct anterior approach between May 2018 and January 2024. Operation time, length of hospital stay, and postoperative complications were recorded. Changes in hematological parameters, including hemoglobin, blood urea nitrogen, and serum potassium levels, were evaluated preoperatively and postoperatively. Clinical outcomes were assessed using the visual analogue scale (VAS) for pain, Harris Hip Score, and Oxford Hip Score (OHS), along with radiographic evaluation.Results All 10 patients were followed up for 14-61 months postoperatively, with an average follow-up period of 31.5 months. Operation time ranged for 80-165 min, with an average of 101 min, and hospitalisation ranged for 7-12 d, with an average of 9.6 d. All wounds healed in stage I, and at the final follow-up, there were no serious adverse events such as joint infection, periprosthetic fracture, or surgery-related death. There was no significant difference in hematological indices before and after operation. The VAS, HHS and OHS scores showed significant improvement at the last follow-up compared to pre-surgery levels, with a statistically significant difference (P<0.05).Conclusion With individualized perioperative management, minimally invasive total hip arthroplasty via the direct anterior approach can effectively relieve pain and significantly improve hip function in patients with uremia, with a relatively low incidence of complications. These findings suggest that this surgical approach is both feasible and safe for this high-risk population. |
